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a bs t r ac t
BACKGROUND

The survival benefit of a strategy of coronary-artery bypass grafting (CABG) added to
guideline-directed medical therapy, as compared with medical therapy alone, in patients with coronary artery disease, heart failure, and severe left ventricular systolic
dysfunction remains unclear.
METHODS

From July 2002 to May 2007, a total of 1212 patients with an ejection fraction of 35%
or less and coronary artery disease amenable to CABG were randomly assigned to
undergo CABG plus medical therapy (CABG group, 610 patients) or medical therapy
alone (medical-therapy group, 602 patients). The primary outcome was death from any
cause. Major secondary outcomes included death from cardiovascular causes and death
from any cause or hospitalization for cardiovascular causes. The median duration of
follow-up, including the current extended-follow-up study, was 9.8 years.
RESULTS

A primary outcome event occurred in 359 patients (58.9%) in the CABG group and in
398 patients (66.1%) in the medical-therapy group (hazard ratio with CABG vs. medical
therapy, 0.84; 95% confidence interval [CI], 0.73 to 0.97; P = 0.02 by log-rank test). A
total of 247 patients (40.5%) in the CABG group and 297 patients (49.3%) in the
medical-therapy group died from cardiovascular causes (hazard ratio, 0.79; 95% CI,
0.66 to 0.93; P = 0.006 by log-rank test). Death from any cause or hospitalization for
cardiovascular causes occurred in 467 patients (76.6%) in the CABG group and in 524
patients (87.0%) in the medical-therapy group (hazard ratio, 0.72; 95% CI, 0.64 to 0.82;
P<0.001 by log-rank test).
CONCLUSIONS

In a cohort of patients with ischemic cardiomyopathy, the rates of death from any
cause, death from cardiovascular causes, and death from any cause or hospitalization
for cardiovascular causes were significantly lower over 10 years among patients who
underwent CABG in addition to receiving medical therapy than among those who received medical therapy alone. (Funded by the National Institutes of Health; STICH [and
STICHES] ClinicalTrials.gov number, NCT00023595.)
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A

dvances in the management of
cardiovascular risk factors and acute coronary syndromes have increased survival
among patients with coronary artery disease,
transforming it into a chronic disease that affects
15.5 million U.S. patients; however, coronary artery disease still accounts for more than 538,000
deaths yearly in the United States alone.1 The
major long-term manifestations of coronary artery disease, left ventricular dysfunction, and
heart failure are projected to affect 8 million
patients by 2030, which has enormous societal
implications.1
Landmark clinical trials have established coronary-artery bypass grafting (CABG) as an effective treatment for patients with disabling angina
symptoms.2-4 In these trials, CABG was associated with longer survival than was medical therapy
alone among the subgroups with more extensive
coronary artery disease and worse left ventricular dysfunction.5 However, the trials were conducted more than 40 years ago, before the availability of current guideline-based medical therapy
for coronary artery disease and heart failure,6,7
and they did not include patients with severe left
ventricular dysfunction; only 4% of participants
had symptomatic heart failure.8 More recently,
an increasing proportion of patients with heart
failure and left ventricular dysfunction are referred for CABG.9
The Surgical Treatment for Ischemic Heart
Failure (STICH) study consisted of two trials —
a surgical revascularization component and a
surgical ventricular reconstruction component.
The surgical revascularization component was
designed to test the hypothesis that CABG plus
guideline-directed medical therapy for coronary
artery disease, heart failure, and left ventricular
dysfunction would improve survival over that
with medical therapy alone. In the analysis of
data from the surgical revascularization component of the STICH study at a median follow-up
of 56 months, there was no significant difference between the CABG group and the medicaltherapy group in the rate of death from any
cause, although the rates of death from cardiovascular causes and of death from any cause or
hospitalization for cardiovascular causes were
lower among patients in the CABG group.10 We
now report the results of the STICH Extension
Study (STICHES), which was conducted to evaluate the long-term (10-year) effects of CABG in
patients with ischemic cardiomyopathy.
1512
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Me thods
Study Design

The design and enrollment characteristics of the
STICH study have been published previously, as
have the intermediate-term results of the surgical revascularization component and the final
results of the surgical ventricular reconstruction
component.10-13 The protocol (available with the
full text of this article at NEJM.org) was approved by the principal investigator and by the
ethics committee at each center. Before the
treatment-group assignments were revealed or
any intermediate-term results were reported, the
protocol was amended to extend the follow-up
period by an additional 5 years for all patients
who were enrolled in the surgical revascularization component of the study. The Duke Clinical
Research Institute coordinated all aspects of
global trial operations, site management and
monitoring, data collection, statistical analyses,
and reporting. All the authors assume responsibility for the completeness and accuracy of the
data and the analyses and for the fidelity of the
trial to the protocol.
Patients

Patients were eligible for participation in the
trial if they had coronary artery disease that was
amenable to CABG and an ejection fraction of
35% or lower. Detailed enrollment criteria, including randomization strata criteria, have been
published previously10 and are provided in Table
S1 in the Supplementary Appendix, available at
NEJM.org. Eligibility for participation was determined by site investigators after each patient
underwent direct coronary angiography. Patients
who did not have a left main coronary artery
stenosis of 50% or more of the artery diameter
or Canadian Cardiovascular Society class III or
IV angina (with classes ranging from I to IV, and
higher values indicating more disabling pain due
to angina) while they were receiving medical
therapy were eligible for random assignment to
either the CABG group or the medical-therapy
group. By design, in our trial, patients who met
these criteria but did not meet the criteria for
eligibility for surgical ventricular reconstruction
(dominant anterior left ventricular akinesia or
dyskinesia) were enrolled in stratum A, whereas
patients who did meet the criteria for eligibility
for surgical ventricular reconstruction were
enrolled in stratum B; patients were included in

nejm.org

April 21, 2016

The New England Journal of Medicine
Downloaded from nejm.org at NEW YORK MEDICAL COLLEGE on January 4, 2017. For personal use only. No other uses without permission.
Copyright © 2016 Massachusetts Medical Society. All rights reserved.

Coronary-Artery Bypass Surgery for Ischemic Cardiomyopathy

the current analysis only if they were assigned to Statistical Analyses
CABG or medical therapy. All patients provided The statistical methods used for comparative
written informed consent.
treatment analyses that included data from the
extended follow-up period were similar to those
Trial Procedures
used in the original STICH study.10 All major
At the initial evaluation, a baseline physical ex- comparisons were performed according to the
amination was performed, and baseline demo- intention-to-treat principle — that is, treatment
graphic and clinical data (including information groups were defined according to the original
regarding current medications and previous diag- randomization. Two-sided significance testing
nostic and other cardiovascular procedures) were was used for all statistical tests. The cumulative
obtained. Random assignment to either CABG event rates were calculated according to the
or medical therapy was accomplished with the Kaplan–Meier method,14 with event or censoring
use of an interactive voice-response system.
times calculated from the date of randomizaThroughout the trial follow-up period, the use tion. The significance of the differences in
of guideline-recommended medications and de- outcomes between the treatment groups was
vices for the treatment of heart failure and coro- assessed with the use of the log-rank test, with
nary artery disease was strongly emphasized for adjustment for randomization stratum (A or B,
all patients. Patients assigned to CABG were to as described previously).10 Relative risks were
undergo the procedure within 14 days after ran- expressed as hazard ratios with associated condomization. CABG was performed by preapproved fidence intervals and were calculated with the
study surgeons who had provided documentation Cox proportional-hazards model.15 The consisof an operative mortality of 5% or lower among tency of treatment effects across a number of
patients whose risk of complications was similar prespecified subgroups, including those defined
to that of patients in our trial. During the enroll- according to age, sex, race and ethnic backment period, a surgical therapy committee mon- ground, geographic region, randomization straitored the overall mortality and rates of compli- tum, heart failure class, left ventricular ejection
cations associated with the CABG procedures.
fraction, angina class, and number of diseased
All patients had follow-up evaluations at the vessels, was examined by testing for interactions
time of discharge or at 30 days after randomiza- between treatment and these baseline charactertion, then every 4 months for the first year and istics with the use of the Cox model. To assess
every 6 months thereafter. During the extended the robustness of the log-rank results with
follow-up period, if a patient was unwilling or crossing of hazard functions, post hoc analyses
unable to return to the enrolling center, follow- without an assumption of constant relative risks
up was maintained by the enrolling investigator were also performed.16,17
through telephone contact or was transferred,
To assess the effect of early crossovers befor follow-up either in person or by telephone, to tween treatment groups (within the first year),
a lead regional investigator under the oversight secondary as-treated and per-protocol analyses
were also performed. The as-treated compariof local ethics boards.
son was performed with the use of a Cox model
Outcomes
in which CABG was incorporated as a timeThe primary outcome was death from any cause. dependent covariate.
The prespecified secondary outcomes included
The final clinical assessment for surviving
death from cardiovascular causes, death from patients was performed during the 6-month peany cause or hospitalization for cardiovascular riod before November 30, 2015, which was the
causes, death from any cause or hospitalization cutoff date for the extended follow-up. Patients
for heart failure, death from any cause or hospi- who provided documentation declining further
talization for any cause, and death from any participation at any point were classified as havcause or revascularization. The adjudication of ing withdrawn, whereas patients whose last conthe cause of death according to prespecified tact occurred before June 1, 2015, were classified
criteria was conducted by an independent clin- as lost to follow-up.
ical-events committee, the members of which
Throughout the extended follow-up period, an
were unaware of the treatment assignments (see independent data and safety monitoring board
the Supplementary Appendix).
appointed by the National Heart, Lung, and
n engl j med 374;16
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Blood Institute met yearly to review the progress
of the trial, ensure the safety of the participants,
and assess the overall integrity of the follow-up
data. Formal interim efficacy analyses were not
planned during the extended follow-up period.
For the final analysis, a P value of 0.05 or less
was considered to indicate statistical significance. All analyses were performed with the use
of SAS software, version 9.3 or higher (SAS Institute). The final statistical analysis plan was
approved by the trial executive committee before
the database lock (see the Supplementary Appendix).

R e sult s
Study Population

of

m e dic i n e

out the study period. There were no significant
differences between the treatment groups with
regard to the frequency of the use of guidelinedirected medication at baseline (Table S4 in the
Supplementary Appendix).
Follow-up

The median duration of follow-up among all
patients was 9.8 years (interquartile range, 9.1 to
11.0); the minimum was 3.5 years, and the
maximum was 13.4 years. Details regarding
follow-up are provided in Figure 1.
The final follow-up status was ascertained for
1187 patients (97.9%) between June 1 and November 30, 2015. Among the 25 patients who could
not be evaluated during the final follow-up period, 6 withdrew consent for further follow-up, and
19 could not be located by site investigators. The
median time from randomization to the date of
last contact for patients who withdrew from the
trial or were lost to follow-up was 6.4 years (interquartile range, 5.9 to 8.1).

Between July 24, 2002, and May 5, 2007, a total
of 1212 patients across 99 sites in 22 countries
were randomly assigned to receive CABG (610
patients) or medical therapy (602 patients) (Table
S2 in the Supplementary Appendix). The characteristics of the patients at baseline, including
ventricular function and coronary anatomy, were Outcomes
similar in the two groups (Table 1, and Table S3 A primary outcome event (death from any cause)
in the Supplementary Appendix).
occurred in 359 of 610 patients (58.9%) in the
CABG group and in 398 of 602 patients (66.1%)
Procedures
in the medical-therapy group (hazard ratio with
Among the 610 patients who were randomly as- CABG vs. medical therapy, 0.84; 95% confidence
signed to the CABG group, 555 (91.0%) under- interval [CI], 0.73 to 0.97; P = 0.02 by log-rank
went CABG before completion of the trial; the test) (Table 2 and Fig. 2A, and Table S5 in the
median time from randomization to CABG was Supplementary Appendix). The median survival
10 days (interquartile range, 5 to 16), and the was 7.73 years among patients in the CABG group
maximum was 177 days. Among the patients and 6.29 years among patients in the medicalwho were randomly assigned to the CABG group therapy group; median survival was 1.44 years
and underwent CABG, 505 (91.0%) received at longer in the CABG group, and the number
least one arterial conduit, and 473 of the 553 needed to treat to prevent one death was 14 papatients for whom data were available (85.5%) tients (95% CI, 8 to 55). Post hoc analyses withreceived one or more venous conduits. Addi- out an assumption of constant relative risks
tional details of the surgical procedures have showed significance similar to the values in the
been published previously.18
prespecified log-rank test.
Among the 602 patients who were randomly
A total of 247 patients (40.5%) in the CABG
assigned to the medical-therapy group, 119 group and 297 (49.3%) in the medical-therapy
(19.8%) had CABG performed at any time before group died from cardiovascular causes (hazard
the completion of long-term follow-up; 66 pa- ratio, 0.79; 95% CI, 0.66 to 0.93; P = 0.006 by logtients (11.0%) underwent CABG within the first rank test) (Table 2 and Fig. 2B). Death from any
year of follow-up. The median time to CABG was cause or hospitalization for cardiovascular causes
6.9 months (interquartile range, 1.2 to 33.6). The occurred in 467 patients (76.6%) in the CABG
indications for crossovers between the treatment group and in 524 (87.0%) patients in the medigroups within the first year have been published cal-therapy group (hazard ratio, 0.72; 95% CI,
0.64 to 0.82; P<0.001 by log-rank test) (Table 2
previously.19
The frequency of the use of guideline-direct- and Fig. 2C). The results for other prespecified
ed medication was high at baseline and through- secondary outcomes and additional outcomes
1514
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Table 1. Characteristics of the Patients at Baseline.*
CABG Group
(N = 610)

Medical-Therapy Group
(N = 602)

Median age (IQR) — yr

60 (54–68)

59 (53–67)

Female sex — no. (%)

73 (12)

75 (12)

221 (36)

200 (33)

Characteristic

Race or ethnic group — no. (%)†
Hispanic, Latino, or nonwhite
White

389 (64)

402 (67)

27 (24–30)

27 (24–30)

Previous myocardial infarction

462 (76)

472 (78)

Hyperlipidemia

360 (59)

370 (62)§

Hypertension

358 (59)

370 (61)

Diabetes

Median body-mass index (IQR)‡
Medical history — no. (%)

240 (39)

238 (40)

Previous stroke

51 (8)

41 (7)

Chronic renal insufficiency

49 (8)

45 (7)

Previous percutaneous coronary intervention

82 (13)

74 (12)

Previous CABG

22 (4)

14 (2)

130 (21)

122 (20)

Current smoker — no. (%)
CCS angina class — no. (%)¶
No angina

217 (36)

225 (37)

I

96 (16)

91 (15)

II

265 (43)

260 (43)

III

25 (4)

23 (4)

IV

7 (1)

3 (<1)

NYHA heart failure class — no. (%)¶
I

65 (11)

74 (12)

II

319 (52)

307 (51)

III

207 (34)

205 (34)

IV
Median systolic blood pressure (IQR) — mm Hg
Median pulse rate (IQR) — beats/min
Median 6-min walk distance (IQR) — ft‖

19 (3)

16 (3)

120 (110–130)

120 (110–130)

74 (66–82)

72 (65–80)

1145 (863–1320)

1115 (840–1345)

*	There were no significant differences in baseline characteristics between the treatment groups. CABG denotes coronaryartery bypass grafting, and IQR interquartile range.
†	Race and ethnic group were self-reported.
‡	The body-mass index is the weight in kilograms divided by the square of the height in meters.
§	Data on hyperlipidemia were missing for 1 patient.
¶	The Canadian Cardiovascular Society (CCS) angina classes range from I to IV, with higher classes indicating more disabling
pain due to angina. New York Heart Association (NYHA) heart failure classes range from I to IV, with higher values indicating greater disability.
‖	To convert the values for the 6-minute walk distance to meters, multiply by 0.305.

are provided in Table 2. The results of the covariate-adjusted models, including those with CABG
as a time-dependent covariate, are provided in
Table S6 in the Supplementary Appendix. Among
the patients in the CABG group, 2 had a repeat
n engl j med 374;16

CABG during follow-up. A left ventricular assist
device was inserted in 4 patients in the CABG
group and in 2 patients in the medical-therapy
group. Five patients underwent heart transplantation during follow-up: 1 patient in the CABG
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Table 2. Primary and Secondary Outcomes.
CABG
Group
(N = 610)

Outcomes

Medical-Therapy
Group
(N = 602)

Hazard Ratio
(95% CI)*

P Value*

0.84 (0.73–0.97)

0.02

no. of patients (%)
Primary outcome: death from any cause

359 (58.9)

398 (66.1)

Secondary outcomes
Death from cardiovascular causes

247 (40.5)

297 (49.3)

0.79 (0.66–0.93)

0.006

Death from any cause or hospitalization for cardiovascular causes

467 (76.6)

524 (87.0)

0.72 (0.64–0.82)

<0.001

Death from any cause or hospitalization for heart failure

404 (66.2)

450 (74.8)

0.81 (0.71–0.93)

0.002

Death from any cause or hospitalization for any cause

506 (83.0)

538 (89.4)

0.81 (0.71–0.91)

0.001

Death from any cause or revascularization†

388 (63.6)

478 (79.4)

0.63 (0.55–0.73)

<0.001

Death from any cause or nonfatal myocardial infarction‡

376 (61.6)

409 (67.9)

0.86 (0.74–0.98)

0.03

Death from any cause or nonfatal stroke‡

367 (60.2)

406 (67.4)

0.85 (0.74–0.98)

0.03

*	Hazard ratios (CABG vs. medical therapy) are based on the Cox model, and the associated P values are based on the log-rank test. All assessments were adjusted for patient stratum (A vs. B: patients who met the eligibility criteria for random assignment to the CABG group or
medical-therapy group but did not meet the criteria for eligibility for surgical ventricular reconstruction were enrolled in stratum A; patients
who did meet the criteria for eligibility for surgical ventricular reconstruction were enrolled in stratum B).
†	The method of revascularization was either percutaneous coronary intervention or CABG.
‡	Death or nonfatal myocardial infarction and death or nonfatal stroke were not prespecified outcomes.

1212 Patients underwent randomization

610 Were assigned to undergo
CABG plus medical therapy

602 Were assigned to receive
medical therapy alone

Intermediate results: median follow-up, 4.9 yr
218 Died
392 Survived

Intermediate results: median follow-up, 4.9 yr
244 Died
358 Survived

13 Withdrew or were lost
to follow-up

12 Withdrew or were lost
to follow-up

610 Were included in long-term follow-up
analyses (median follow-up, 9.9 yr;
maximum follow-up, 13.3 yr)

602 Were included in long-term follow-up
analyses (median follow-up, 9.8 yr;
maximum follow-up, 13.4 yr)

Figure 1. Randomization and Follow-up.
CABG denotes coronary-artery bypass grafting.

group and 4 patients in the medical-therapy group.
During the entire follow-up period, 105 patients
(17.2%) in the CABG group and 118 patients
(19.6%) in the medical-therapy group received an
implantable cardioverter–defibrillator (alone or
in combination with cardiac resynchronization
1516
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therapy). A percutaneous coronary intervention
was performed in 43 patients (7.0%) in the CABG
group and in 50 patients (8.3%) in the medicaltherapy group. A list of all postrandomization
adverse events is provided in Table S7 in the
Supplementary Appendix.
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Among the 591 patients who did not undergo
CABG within 1 year (55 in the CABG group and
536 in the medical-therapy group), 402 (68.0%)
died during follow-up; among the 621 patients
who underwent CABG either as randomly assigned or as a treatment crossover from the
medical-therapy group within the first year after
randomization, 355 (57.2%) died during followup (hazard ratio, 0.75; 95% CI, 0.65 to 0.87;
P<0.001) (Fig. S1 in the Supplementary Appendix).
We also performed a per-protocol analysis comparing the 536 patients in the medical-therapy
group who did not cross over to CABG within
the first year with the 555 patients in the CABG
group who actually received CABG within the
first year; the hazard ratio with CABG as compared with medical therapy alone was 0.77 (95%
CI, 0.67 to 0.90; P = 0.001 by the log-rank test)
(Fig. S2 in the Supplementary Appendix).

A Death from Any Cause (Primary Outcome)
100

Hazard ratio, 0.84 (95% CI, 0.73–0.97)
P=0.02 by log-rank test

90
80

Medical therapy

70

Event Rate (%)

Analysis of Crossovers

60

CABG

50
40
30
20
10
0

0

1

2

3

4

5

6

7

8

9

10

11

602 532 487 435 404 357 315 274 248 164 82
610 532 487 460 432 392 356 312 286 205 103

37
42

Years since Randomization
No. at Risk
Medical therapy
CABG

B Death from Cardiovascular Causes
100

Hazard ratio, 0.79 (95% CI, 0.66–0.93)
P=0.006 by log-rank test

90
80
70

Event Rate (%)

Subgroup Analyses

Subgroup analyses based on demographic and
clinical characteristics of interest reflected the
broad consistency of the effect of CABG on
the primary outcome (Fig. 3). An exception was
the nominally significant interactions of treatment with randomization stratum, race, and
number of diseased vessels with 75% or greater
stenosis.

Medical therapy

60
50

CABG

40
30
20
10
0

0

1

2

3

4

5

6

7

8

9

10

11

602 532 487 435 404 357 315 274 248 164 82
610 532 487 460 432 392 356 312 286 205 103

37
42

Years since Randomization
No. at Risk
Medical therapy
CABG

In this randomized clinical trial involving patients with heart failure, left ventricular dysfunction, and coronary artery disease, the rate of
death from any cause over 10 years was lower by
16% (an 8-percentage-point absolute difference
in the 10-year Kaplan–Meier rates) among patients who underwent CABG in addition to receiving medical therapy than among those who
received medical therapy alone. Overall, CABG
was associated with an incremental median survival benefit of nearly 18 months and prevention
of one death due to any cause for every 14 patients treated and of one death due to a cardiovascular cause for every 11 patients treated.
CABG was associated with more favorable
results than medical therapy alone across all
clinically relevant long-term outcomes we evaluated. These findings were directionally similar
to those reported earlier on the basis of a median follow-up period of 56 months.10 We believe
n engl j med 374;16

C Death from Any Cause or Cardiovascular Hospitalization
100

Hazard ratio, 0.72 (95% CI, 0.64–0.82)
P<0.001 by log-rank test

90
80

Event Rate (%)

Discussion

Medical therapy
CABG

70
60
50
40
30
20
10
0

0

1

2

3

4

5

6

7

8

9

10

98
166

57
106

19
43

Years since Randomization
No. at Risk
Medical therapy
CABG

602
610

385
431

314
376

259
334

219
293

185
259

152
218

123
184

Figure 2. Kaplan–Meier Estimates of the Rates of Death from Any Cause, Death
from Cardiovascular Causes, and Death from Any Cause or Hospitalization
for Cardiovascular Causes.
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that the further statistical separation between
the groups that we now report resulted from a
persistent and perhaps increasing effect size over
time, coupled with the enhanced precision of estimates afforded by the greater number of events.
We previously reported that CABG was associated
with a risk of death within the initial 30 days
after randomization that was triple the risk with
medical therapy alone, with similar differences in
risk up to the second year of follow-up, before a
significant benefit began to accrue after 2 years.
Thus, it appears that the operative risk associated with CABG is offset by a durable effect that
translates into increasing clinical benefit to at
least 10 years. The lack of convergence of the
curves over this prolonged period of follow-up
contrasts with other long-term follow-up studies
involving patients with heart failure and severe
left ventricular systolic dysfunction and underscores the lasting benefits of CABG.20,21 Furthermore, the analyses of the as-treated and perprotocol populations suggest that crossovers
between the treatment groups diminished the
effect of CABG observed when the data were
analyzed according to the assigned group and
that the mortality associated with CABG may be
as much as 20 to 25% lower than that associated
with medical therapy, under the assumption that
the surgical mortality in routine clinical practice
is similar to or lower than that reported in our
trial.
Substantial declines in risk-adjusted mortality
associated with CABG have occurred since the
1970s, when the landmark trials comparing
CABG and medical therapy were performed. Improvements in myocardial protection techniques,
surgical skill, and perioperative care, coupled
with the near-universal use of the left internal
mammary artery (LIMA) conduit are probably
responsible. Among the patients randomly assigned to undergo CABG, 91.0% of patients in
STICH received a LIMA graft, as compared with
9.9% of patients in the early CABG trials.8 Although there are limited data on the long-term
patency of LIMA or saphenous vein grafts in patients at high risk for death or complications,
like those enrolled in STICH, evidence from
studies involving lower-risk patients supports
the superior 1-year angiographic results with the
LIMA.22 In addition, the high rate of use of
statins, which have been shown to reduce the
rate of vein-graft failure,23,24 is likely to have
contributed to the durable effect of CABG and
1518
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Figure 3 (facing page). Subgroup Analyses of Death
from Any Cause.
Age, sex, race, region, New York Heart Association
(NYHA) heart failure class, left ventricular ejection
fraction (LVEF), stratum, Canadian Cardiovascular
Society (CCS) angina class, and number of diseased
vessels are prespecified subgroup factors. All other
variables are post hoc subgroup factors. All subgroups
are based on values measured at baseline. Data on
ESVI were missing for 97 patients, data on the number
of vessels with 75% or greater stenosis and on the degree of stenosis of the left main coronary artery (LM)
and proximal left anterior descending artery (PLAD)
were missing for 1 patient, and data on mitral regurgitation were missing for 3 patients. The Canadian Cardiovascular Society (CCS) angina classes range from I to
IV, with higher classes indicating more disabling pain
due to angina. New York Heart Association (NYHA)
heart failure classes range from I to IV, with higher values
indicating greater disability. The divisions between the
LVEF and the end-systolic volume index subgroups were
based on the median values. Patients who met the eligibility criteria for random assignment to the CABG
group or medical-therapy group but did not meet the
criteria for eligibility for surgical ventricular reconstruction were enrolled in stratum A; patients who did meet
the criteria for eligibility for surgical ventricular reconstruction were enrolled in stratum B.

the low rates of repeat revascularization observed in this group.
Ischemic cardiomyopathy remains a high-risk
and lethal condition, as indicated by an observed
overall mortality of 62.5% with a median followup of 9.8 years, even on the background of
guideline-directed medical therapy. Patients with
heart failure and left ventricular dysfunction
have abnormalities of coronary hemodynamics
and myocardial energetics during rest, including
an increase in myocardial oxygen consumption
and altered myocardial lactate metabolism, even
in the absence of epicardial coronary artery disease.25,26 Coronary disease compounds the already
unfavorable myocardial conditions and limited
cardiac reserve in these patients. The significant
subgroup interaction we noted between treatment and the extent of coronary artery disease is
consistent with previous analyses involving this
trial population, which indicated a greater benefit
of CABG in patients with three-vessel coronary
artery disease than among patients with onevessel or two-vessel disease27; it is also consistent
with observations in studies involving cohorts of
lower-risk patients with coronary artery disease
who were treated before the current advances in
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Subgroup

No. of Patients

0.84 (0.73–0.97)

All patients
1212
Age
589
≥60 yr
623
<60 yr
Sex
1064
Male
148
Female
Race or ethnic group
421
Hispanic, Latino, or nonwhite
791
White
Region or country
319
Poland
120
United States
123
Canada
112
Western Europe
538
Other
NYHA heart failure class
765
I or II
447
III or IV
LVEF
653
≤28%
559
>28%
End-systolic volume index
564
≤78 ml/m2
>78 ml/m2
551
Stratum
A
1061
B
151
Diabetes
Yes
478
No
734
CCS angina class
No angina or I
629
II, III, or IV
583
No. of diseased vessels with ≥75% stenosis
769
0, 1, or 2
442
3
LM ≥50% or PLAD ≥75% stenosis
373
No
838
Yes
Mitral regurgitation
435
None or trace
554
Mild (≤2+)
220
Moderate or severe (3+ or 4+)
0.25

P Value for
Interaction

Hazard Ratio (95% CI)

0.18
0.91 (0.75–1.10)
0.75 (0.60–0.93)
0.50
0.85 (0.73–0.99)
0.73 (0.46–1.16)
0.02
0.67 (0.52–0.86)
0.95 (0.80–1.12)
0.28
1.01 (0.77–1.33)
0.85 (0.55–1.31)
0.77 (0.48–1.22)
1.08 (0.68–1.69)
0.72 (0.57–0.89)
0.74
0.85 (0.71–1.02)
0.81 (0.65–1.01)
0.31
0.77 (0.64–0.92)
0.89 (0.71–1.11)
0.68
0.85 (0.68–1.06)
0.80 (0.65–0.98)
0.03
0.89 (0.77–1.04)
0.55 (0.36–0.84)
0.95
0.84 (0.67–1.04)
0.84 (0.69–1.01)
0.52
0.80 (0.65–0.97)
0.88 (0.72–1.09)
0.04
0.93 (0.77–1.11)
0.68 (0.54–0.86)
0.81
0.81 (0.62–1.05)
0.85 (0.71–1.00)
0.34
0.92 (0.71–1.17)
0.74 (0.60–0.92)
0.94 (0.68–1.29)
0.50

1.0

CABG Better

medical therapy, which indicated that CABG
may provide the greatest benefit to the patients
who have the most extensive heart disease.8,28
By design, in this trial, both the enrolled patients and the site investigators were aware of
the treatment-group assignments, and this lack
of blinding may have affected the rates of revascularization procedures. We acknowledge this as
n engl j med 374;16

2.0

4.0

Medical Therapy Better

a limitation of our trial, especially as it relates to
the interpretation of nonfatal events. Unmeasured
confounding owing to differences in subsequent
care cannot be ruled out; however, we found
high and similar rates of medical therapy and
follow-up in both groups. It is not known
whether percutaneous coronary revascularization
as compared with medical therapy alone would
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result in benefits similar to those that we observed with CABG.
In summary, the results of the STICH Extension Study support a significant benefit of CABG
plus medical therapy over medical therapy alone
with respect to the rate of death from any cause
among patients with ischemic cardiomyopathy.
This work is solely the responsibility of the authors and does
not necessarily represent the official views of the National Heart,
Lung, and Blood Institute of the National Institutes of Health.
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